
Midatech Pharma plc MTP
Annual report 2024
added 12-27-2025
Midatech Pharma plc Operating Income 2011-2026 | MTP
Operating profit (also called operating income or profit from core activities) is a financial metric that reflects a company's profit from its main operational activities before interest expenses and taxes are taken into account.
FormulaOperating profit = Revenue – Operating expensesFeatures of the metric
- Evaluates business efficiency
Shows how well the company controls its production and administrative costs. - Independent of financial structure
Excludes the impact of debt burden (interest) and taxes, allowing objective comparison of companies. - Main source for growth
High operating profit provides resources for investments, business expansion, and increased competitiveness.
If a company shows strong operating profit, it signals to investors that the core business is operating efficiently, even if net profit is temporarily reduced due to debt or tax burden.
Annual Operating Income Midatech Pharma plc
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | -7 M | -23 M | -11.3 M | -11.8 M | -13.3 M | -9.65 M | -12.9 M | - | - | - | - |
All numbers in GBP currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -7 M | -23 M | -12.7 M |
Operating Income of other stocks in the Biotechnology industry
| Issuer | Operating Income | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
AgeX Therapeutics
AGE
|
-9.89 M | - | -10.17 % | $ 12.2 K | ||
|
AIkido Pharma
AIKI
|
-11.5 M | - | 1.93 % | $ 17.4 M | ||
|
MorphoSys AG
MOR
|
-508 M | - | 2.43 % | $ 254 M | ||
|
Aclaris Therapeutics
ACRS
|
-142 M | $ 2.86 | -4.98 % | $ 221 M | ||
|
AlloVir
ALVR
|
-65.4 M | - | 4.14 % | $ 49.1 M | ||
|
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
|
-704 M | $ 10.75 | -4.78 % | $ 695 M | ||
|
Ampio Pharmaceuticals
AMPE
|
-33.3 M | - | -11.43 % | $ 502 K | ||
|
Alpine Immune Sciences
ALPN
|
-58.1 M | - | - | $ 2.17 B | ||
|
Applied Molecular Transport
AMTI
|
-127 M | - | - | $ 10.1 M | ||
|
Biophytis SA
BPTS
|
-26.8 M | - | -13.47 % | $ 169 M | ||
|
Aeglea BioTherapeutics
AGLE
|
-209 M | - | - | $ 1.01 B | ||
|
Avenue Therapeutics
ATXI
|
-11.3 M | - | -52.27 % | $ 4.45 M | ||
|
Autolus Therapeutics plc
AUTL
|
-241 M | $ 1.9 | -4.77 % | $ 485 M | ||
|
AVROBIO
AVRO
|
10.2 M | - | 1083.1 % | $ 745 M | ||
|
Ascendis Pharma A/S
ASND
|
-452 M | $ 211.51 | -0.81 % | $ 5 B | ||
|
Can-Fite BioPharma Ltd.
CANF
|
-8.13 M | $ 0.21 | 3.0 % | $ 457 M | ||
|
BioDelivery Sciences International
BDSI
|
37.1 M | - | -4.8 % | $ 255 M | ||
|
BioVie
BIVI
|
-18.1 M | $ 1.33 | 14.66 % | $ 1.96 M | ||
|
Athersys
ATHX
|
-87.1 M | - | 3.77 % | $ 22.4 M | ||
|
CASI Pharmaceuticals
CASI
|
-41.8 M | $ 0.81 | -4.71 % | $ 110 M | ||
|
Catalyst Biosciences
CBIO
|
-67.2 M | $ 11.12 | -6.28 % | $ 732 M | ||
|
Bellicum Pharmaceuticals
BLCM
|
-27 M | - | -9.72 % | $ 5.89 M | ||
|
Berkeley Lights
BLI
|
-98.1 M | - | -7.31 % | $ 87 M | ||
|
ARCA biopharma
ABIO
|
-88.1 M | - | 1052.0 % | $ 415 M | ||
|
Certara
CERT
|
-1.73 M | $ 8.73 | -0.91 % | $ 1.4 B | ||
|
Acasti Pharma
ACST
|
-16.7 M | - | 4.01 % | $ 150 M | ||
|
Adaptimmune Therapeutics plc
ADAP
|
-140 M | - | -15.15 % | $ 60.3 M | ||
|
bluebird bio
BLUE
|
-244 M | - | - | $ 546 M | ||
|
Albireo Pharma
ALBO
|
-123 M | - | -0.23 % | $ 916 M | ||
|
BioNTech SE
BNTX
|
15.3 B | $ 96.21 | 1.06 % | $ 27.2 B | ||
|
Calithera Biosciences
CALA
|
-115 M | - | -10.95 % | $ 876 K | ||
|
Amphastar Pharmaceuticals
AMPH
|
205 M | $ 26.13 | -2.41 % | $ 1.27 B | ||
|
BeiGene, Ltd.
BGNE
|
-568 M | - | 0.49 % | $ 251 B | ||
|
Cellectis S.A.
CLLS
|
-131 M | $ 4.77 | -1.45 % | $ 116 M | ||
|
Anika Therapeutics
ANIK
|
-87.6 M | $ 9.31 | -3.12 % | $ 136 M | ||
|
Arena Pharmaceuticals
ARNA
|
-624 M | - | -6.81 % | $ 3.04 B | ||
|
Acer Therapeutics
ACER
|
-24.6 M | - | 2.71 % | $ 14 M | ||
|
Corcept Therapeutics Incorporated
CORT
|
137 M | $ 36.68 | 5.4 % | $ 3.79 B | ||
|
Celldex Therapeutics
CLDX
|
-195 M | $ 26.99 | -0.63 % | $ 1.74 M | ||
|
Axon Enterprise
AXON
|
58.5 M | $ 561.1 | -1.2 % | $ 42.5 B | ||
|
Ayala Pharmaceuticals
AYLA
|
-37.5 M | - | - | $ 7.46 M | ||
|
Cellectar Biosciences
CLRB
|
-39 M | $ 3.38 | 14.41 % | $ 41.3 M | ||
|
Aytu BioScience
AYTU
|
-7.83 M | $ 2.75 | 5.58 % | $ 17.3 M | ||
|
AstraZeneca PLC
AZN
|
1.06 B | $ 91.61 | -0.35 % | $ 96.9 B | ||
|
Checkpoint Therapeutics
CKPT
|
-56.2 M | - | - | $ 169 M |